july 14

week of 7/10/2023 - 7/14/2023

Google's Bard AI snubs Canada, doodles turn dynamic with Stable Doodle, healthcare gets a Google Cloud boost, Musk dives into AI with xAI, and brain surgery gets charming.

what to know for now

🌐 Google's Bard AI chatbot bypasses Canada. Amid regulatory hurdles and ongoing investigations, Google's Bard AI, now available in 40 languages across 230 countries, is notably absent in Canada. [Read more]

🎨 Stability AI introduces Stable Doodle, a sketch-to-image tool. The tool converts simple drawings into dynamic images, offering endless creative possibilities for industries ranging from education to arts, and is available for free on the Clipdrop platform. [Read more]

🧠 Anthropic introduces Claude 2, an enhanced AI model. With improved performance, longer responses, and better reasoning skills, Claude 2 demonstrates proficiency in tasks such as coding and math. It's available via API and a beta website, and reports significant improvements in safety, producing fewer harmful outputs. [Read more]

🏥 Google Cloud and Mayo Clinic test AI-powered search tool in healthcare. The tool, called Enterprise Search on Generative AI App Builder, allows clinicians to quickly access patient information across various formats and locations. The technology aims to reduce administrative tasks and prevent physician burnout. [Read more]

what to know for later

👽 Elon Musk launches new AI company, xAI. The venture, aiming to "understand reality", includes a team of AI specialists from notable tech firms like OpenAI, Google Research, and Microsoft Research. [Read more]

📰 OpenAI and Associated Press ink two-year deal for content and tech sharing. The agreement, marking a pioneering move in partnerships between major news companies and AI firms, will see OpenAI license AP's text archive to train its AI models, while AP gains access to OpenAI's technology and expertise. [Read more]

🧠 AI tool CHARM can identify brain tumor's molecular identity during surgery. Developed by scientists, CHARM expedites the process of determining a tumor's DNA, which usually takes days or weeks. This could aid neurosurgeons in making crucial decisions about tissue removal and potential treatments. The tool, however, still requires clinical validation and FDA approval. [Read more]

📬 Want weekly updates delivered to your inbox? Subscribe to the Handy AI newsletter here.